Syenza News — health technology assessment, market access and health economics

Learning Health System Frameworks and AI in US Care: A Scoping Review
A scoping review of 54 learning health system framework studies and 31 AI studies in US care finds that AI work mostly stops at turning data into knowledge. Only three AI studies reached practice, and none described feedback from deployment back into the model. #SyenzaNews #MarketAccess
Recent Posts

NICE Draft Guidance Backs Capsule Sponge Tests for Oesophageal Cancer
Nov 16
CHMP November 2026 Recommends Seven New Medicines for Approval
Nov 16
Baxfendy EU Positive Opinion: CHMP Backs AstraZeneca’s Hypertension Tablet
Nov 16
NHLS Governance Crisis Reaches Parliament With R1.8 Billion in Irregular Spending
Nov 13
Appropriate Comparator Use for EMA-Approved Drugs Fell From 2011 to 2024
Nov 13Syenza's Top Picks

EMA Mid-Year Report 2026: Reform, Supply and the First Joint Clinical Assessment
Nov 4, 2026
CMS Finalizes GLOBE Model Drug Pricing for Medicare Part B Drugs
Nov 9, 2026
Medicare drug price negotiation: CMS sets permanent rules
Nov 9, 2026
Zepbound and Foundayo telehealth access via Hims & Hers
Nov 9, 2026
M72 tuberculosis vaccine approval in Indonesia: BPOM weighs a fast track
Nov 6, 2026
Refixia Nonacog Beta Pegol: INFARMED Recommends Funding for Children Under 12 With Haemophilia B
Nov 6, 2026Latest News

Clinical Guidelines And Protocols
ACS Updates Prostate Cancer Screening Guideline for PSA Testing
“The American Cancer Society has updated its prostate cancer screening guideline, with regular PSA testing for average-risk men aged 50 to 69.” #SyenzaNews #ProstateCancer

Health Policy
SADC Pharmaceutical Pooled Procurement Charter Signed in Durban
The Charter establishing the SADC Pharmaceuticals Pooled Procurement Services was signed in Durban on 12 November 2026, with Tanzania the first Member State to sign. #SyenzaNews #MarketAccess

Clinical Practice
Aspen Gets Approval for Generic Semaglutide in Brazil and South Africa
Aspen Pharmacare has received approval for generic semaglutide in Brazil and South Africa, following Canada in July. Launches in all three markets are expected over the coming months. #SyenzaNews #MarketAccess

Drug Pricing
US MFN Drug Pricing: A 25% German Price Rise Would Cut Medicaid Savings by 3.8%
A preprint led by Thomas Hwang models how German price changes affect US Medicaid MFN savings and German statutory health insurance spending.

Cost Effectiveness Analysis
The EU HTA Regulation: What Latin America Can Learn
A PAHO, RedETSA and HTAi webinar on the EU HTA Regulation: what Latin American agencies can reuse from joint clinical assessments, and which elements may be hard to adapt.

Artificial Intelligence And Machine Learning
Artificial Intelligence in Medicine Regulation: From Concept to Practice
EMA says it is moving artificial intelligence in medicine regulation from concept to practice. Its timeline runs from a 2021 joint workshop to research priorities published in August 2026. #SyenzaNews #MarketAccess #drugregulation

Europe Free account
EMA Draft Guideline on Predictive Biomarker Assays Opens Public Consultation to 31 March 2027
The European Medicines Agency has opened public consultation on its draft guideline on predictive biomarker assays. Comments are accepted from 9 November 2026 until 31 March 2027.

Clinical Practice
FDA Adds Warning on NAION Risk with GLP-1 Receptor Agonists
FDA is requiring every GLP-1 receptor agonist label to carry a warning on NAION, a rare eye condition that can cause permanent vision loss. #SyenzaNews #drugsafety #GLP1

Cardiovascular And Metabolic Diseases
Factor XIa Inhibitor for Stroke Prevention: FDA Approves Sunharbo
The FDA approved Sunharbo (asundexian), the first factor XIa inhibitor for stroke prevention, for adults after a recent ischemic stroke or high-risk TIA. #SyenzaNews #MarketAccess

Cost Effectiveness Analysis
Neuquén Health Technology Assessment Agency: What Law 3563 Sets Up
Law 3563 creates a Neuquén health technology assessment agency. Guadalupe Montero explains how it will weigh safety, benefit, equity and budget impact.
Value Science Weekly
The week in health technology assessment, market access and health economics — what moved, and what it means.



